NDAQ:GILD - Post Discussion
Post by
Higherhopes2020 on Aug 05, 2020 11:18am
Revive Therapeutics U.S. FDA Approval phase 3 trial covid19
evive Therapeutics U.S. FDA Approval phase 3 trial covid19
Revive Therapeutics Ltd. (RVVTF)
Other OTC - Other OTC Delayed Price.
0.3274+0.0774 (+30.96%) UPDATE - Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19
https://stockhouse.com/news/press-releases/2020/08/05/these-are-some-of-the-top-companies-nearing-a-potential-pandemic-treatment
Be the first to comment on this post